{"id":743841,"date":"2013-02-13T09:00:00","date_gmt":"2013-02-13T09:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/"},"modified":"2023-03-22T00:04:41","modified_gmt":"2023-03-22T04:04:41","slug":"merck-statement-on-venezuelan-currency-devaluation","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/","title":{"rendered":"Merck Statement on Venezuelan Currency Devaluation"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Confirms 2013 Full-Year Guidance and Provides Guidance on First        Quarter     <\/p>\n<p>\n      Merck, known as MSD outside the United States and Canada, said today<br \/>\n      that it has completed a preliminary assessment of the impact of the<br \/>\n      Venezuelan government\u2019s intention to devalue its currency effective Feb.<br \/>\n      13, 2013.\n    <\/p>\n<p>\n      As a result of the devaluation, the company will incur a one-time,<br \/>\n      after-tax loss due to exchange of approximately $0.05 per share in the<br \/>\n      first quarter of 2013 related to the remeasurement of the local balance<br \/>\n      sheet at the date of the devaluation. Also, the company expects the<br \/>\n      impact of the devaluation on ongoing operations to be approximately<br \/>\n      $0.02 per share spread over the balance of 2013.\n    <\/p>\n<p>\n      Since Jan. 1, 2010, Venezuela has been designated hyperinflationary and,<br \/>\n      as a result, local foreign operations are remeasured in U.S. dollars<br \/>\n      with the impact recorded in income. On Feb. 8, 2013, the Venezuelan<br \/>\n      government declared its intention to devalue its currency (bol\u00edvar<br \/>\n      fuerte). The official exchange rate is expected to move from 4.30 VEF\/$<br \/>\n      to 6.30 VEF\/$.\n    <\/p>\n<p>\n      The effects of the devaluation do not change the company\u2019s full year<br \/>\n      2013 GAAP (generally accepted accounting principles) or full year<br \/>\n      non-GAAP EPS (earnings per share) guidance ranges.\n    <\/p>\n<p>\n      The company is providing guidance about its expectations for the first<br \/>\n      quarter of 2013, which includes the impact of the devaluation in the<br \/>\n      quarter. Merck expects first-quarter non-GAAP EPS to be between $0.76<br \/>\n      and $0.78, and the GAAP EPS range to be $0.37 to $0.42. A reconciliation<br \/>\n      of anticipated first-quarter 2013 EPS as reported in accordance with<br \/>\n      GAAP to non-GAAP EPS that excludes certain items is provided in the<br \/>\n      table below.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p>\n            $ in millions, except EPS amounts\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>First Quarter 2013<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          GAAP EPS\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $0.37 to 0.42\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Difference<sup>1<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          0.39 to 0.36\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Non-GAAP EPS that excludes items listed below <sup>2<\/sup>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $0.76 to $0,78\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Acquisition-related costs<sup>3<\/sup>\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $1,280 to $1,200\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          175 to 125\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Net decrease (increase) in income before taxes\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          1,455 to 1,325\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Estimated income tax (benefit) expense\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          (255) to (225)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Decrease (increase) in net income\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          $1,200 to $1,100\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      <sup>1<\/sup> Represents the difference between calculated GAAP EPS and<br \/>\n      calculated non-GAAP EPS, which may be different than the amount<br \/>\n      calculated by dividing the impact of the excluded items by the<br \/>\n      weighted-average shares for the period.\n    <\/p>\n<p>\n      <sup>2<\/sup> Merck is providing certain 2013 non-GAAP information that<br \/>\n      excludes certain items because of the nature of these items and the<br \/>\n      impact they have on the analysis of underlying business performance and<br \/>\n      trends. Management believes that providing this information enhances<br \/>\n      investors&#8217; understanding of the company&#8217;s performance. This information<br \/>\n      should be considered in addition to, but not in lieu of, information<br \/>\n      prepared in accordance with GAAP.\n    <\/p>\n<p>\n      <sup>3<\/sup> Includes expenses for the amortization of intangible assets<br \/>\n      and amortization of purchase accounting adjustments to inventories<br \/>\n      recognized as a result of mergers and acquisitions, as well as<br \/>\n      intangible asset impairment charges. Also includes integration and other<br \/>\n      costs associated with mergers and acquisitions.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50563021&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=e84cf7b19ef2707d853683b7839fe68e\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50563021&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=4df15894f184643f800c254dc72670c1\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ron Rogers, 908-423-6449<br \/>Steve Cragle,        908-423-3461<br \/>Investor:<br \/>Carol Ferguson, 908-423-4465<br \/>Justin        Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Confirms 2013 Full-Year Guidance and Provides Guidance on First Quarter Merck, known as MSD outside the United States and Canada, said today that it has completed a preliminary assessment of the impact of the Venezuelan government\u2019s intention to devalue its currency effective Feb. 13, 2013. As a result of the devaluation, the company will incur a one-time, after-tax loss due to exchange of approximately $0.05 per share in the first quarter of 2013 related to the remeasurement of the local balance sheet at the date of the devaluation. Also, the company expects the impact of the devaluation on ongoing operations to be approximately $0.02 per share spread over the balance of 2013. Since Jan. 1, 2010, Venezuela has been designated hyperinflationary and, as a result, local foreign operations are remeasured in U.S. dollars with the impact recorded in income. On Feb. 8, 2013, the Venezuelan government declared its intention to devalue its currency (bol\u00edvar fuerte). The official<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,289],"class_list":["post-743841","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Statement on Venezuelan Currency Devaluation - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Statement on Venezuelan Currency Devaluation - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck Confirms 2013 Full-Year Guidance and Provides Guidance on First Quarter Merck, known as MSD outside the United States and Canada, said today that it has completed a preliminary assessment of the impact of the Venezuelan government\u2019s intention to devalue its currency effective Feb. 13, 2013. As a result of the devaluation, the company will incur a one-time, after-tax loss due to exchange of approximately $0.05 per share in the first quarter of 2013 related to the remeasurement of the local balance sheet at the date of the devaluation. Also, the company expects the impact of the devaluation on ongoing operations to be approximately $0.02 per share spread over the balance of 2013. Since Jan. 1, 2010, Venezuela has been designated hyperinflationary and, as a result, local foreign operations are remeasured in U.S. dollars with the impact recorded in income. On Feb. 8, 2013, the Venezuelan government declared its intention to devalue its currency (bol\u00edvar fuerte). The official\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:41+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-venezuelan-currency-devaluation\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-venezuelan-currency-devaluation\\\/\",\"name\":\"Merck Statement on Venezuelan Currency Devaluation - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-venezuelan-currency-devaluation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-venezuelan-currency-devaluation\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2013-02-13T09:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-venezuelan-currency-devaluation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-venezuelan-currency-devaluation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-venezuelan-currency-devaluation\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-venezuelan-currency-devaluation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Statement on Venezuelan Currency Devaluation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Statement on Venezuelan Currency Devaluation - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/","og_locale":"en_US","og_type":"article","og_title":"Merck Statement on Venezuelan Currency Devaluation - Merck.com","og_description":"Merck Confirms 2013 Full-Year Guidance and Provides Guidance on First Quarter Merck, known as MSD outside the United States and Canada, said today that it has completed a preliminary assessment of the impact of the Venezuelan government\u2019s intention to devalue its currency effective Feb. 13, 2013. As a result of the devaluation, the company will incur a one-time, after-tax loss due to exchange of approximately $0.05 per share in the first quarter of 2013 related to the remeasurement of the local balance sheet at the date of the devaluation. Also, the company expects the impact of the devaluation on ongoing operations to be approximately $0.02 per share spread over the balance of 2013. Since Jan. 1, 2010, Venezuela has been designated hyperinflationary and, as a result, local foreign operations are remeasured in U.S. dollars with the impact recorded in income. On Feb. 8, 2013, the Venezuelan government declared its intention to devalue its currency (bol\u00edvar fuerte). The official","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:41+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/","name":"Merck Statement on Venezuelan Currency Devaluation - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2013-02-13T09:00:00+00:00","dateModified":"2023-03-22T04:04:41+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130213005651r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-venezuelan-currency-devaluation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Statement on Venezuelan Currency Devaluation"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"808bd5eb-efc5-4668-83ef-e3eb65eb7fbc","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Statement-on-Venezuelan-Currency-Devaluation-2013.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743841\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743841"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}